Lupin Limited announced that it has received final approval for its Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% from the United States Food and Drug Administration to market a generic equivalent of Taro Pharmaceuticals North America, Inc.'s Topicort® LP Emollient Cream, 0.05% and Taro Pharmaceuticals, Inc.'s Topicort® Cream, 0.25%. Desoximetasone Cream USP, 0.05% and Desoximetasone Cream USP, 0.25% are the AB rated generic equivalent of Taro's Topicort® LP Emollient Cream, 0.05% and Topicort® Cream, 0.25%. Both products are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topicort® LP emollient Cream had U.S. sales of USD 33 million while Topicort® Cream had U.S. sales of USD 17 million.